Luba Freja Michaelsson1, Bjarke Borregaard Medici1, Jeppe Lerche la Cour2, Christian Selmer1, Michael Røder3, Hans Perrild4, Nils Knudsen4, Jens Faber5, Birte Nygaard1. 1. Department of Endocrinology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark. 2. Department of Endocrinology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark ; Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 3. Department of Medicine, Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark ; Division of Pharmacies and Reimbursement, Danish Health and Medicines Authority, Copenhagen, Denmark. 4. Department of Endocrinology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark. 5. Department of Endocrinology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark ; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Abstract
BACKGROUND: Five to ten percent of patients with hypothyroidism describe persistent symptoms despite being biochemically well regulated on levothyroxine (L-T4). Thyroxine (T4)/triiodothyronine (T3) combination therapy [L-T4/liothyronine (L-T3) or desiccated thyroid] are still regarded as experimental with no evidence of superior effect on persistent symptoms according to meta-analyses. However, some randomized controlled trials have demonstrated patients' preference for T4/T3 combination therapy as compared to L-T4 monotherapy. In 2013, attention to combination therapy increased in Denmark after a patient published a book describing her experiences with hypothyroidism and treatment. OBJECTIVE: To investigate current Danish trends in the use of T4/T3 combination therapy. METHODS: We used an Internet-based questionnaire, distributed as a link via two Danish patient fora. Further, information was obtained from the Division of Pharmacies and Reimbursement at the Danish Health and Medicines Authority and from the only pharmacy in Denmark producing desiccated thyroid and L-T3 tablets. RESULTS: A total of 384 patients answered the questionnaire, and 293 responders were included. Sixty-nine percent of the responders had six or more symptoms, and 84% reported a treatment effect. Forty-four percent of the responders received their prescriptions from general practitioners; 50% received desiccated thyroid and 28% reported that they adjust their dose themselves. Responders followed by general practitioners more frequently received desiccated thyroid and adjusted their dose themselves. CONCLUSIONS: Increased media focus has changed the prescription pattern of thyroid hormones; European guidelines on T4/T3 combination therapy are not always followed in Denmark and many patients adjust their medication themselves and may therefore be at risk of overtreatment.
BACKGROUND: Five to ten percent of patients with hypothyroidism describe persistent symptoms despite being biochemically well regulated on levothyroxine (L-T4). Thyroxine (T4)/triiodothyronine (T3) combination therapy [L-T4/liothyronine (L-T3) or desiccated thyroid] are still regarded as experimental with no evidence of superior effect on persistent symptoms according to meta-analyses. However, some randomized controlled trials have demonstrated patients' preference for T4/T3 combination therapy as compared to L-T4 monotherapy. In 2013, attention to combination therapy increased in Denmark after a patient published a book describing her experiences with hypothyroidism and treatment. OBJECTIVE: To investigate current Danish trends in the use of T4/T3 combination therapy. METHODS: We used an Internet-based questionnaire, distributed as a link via two Danish patient fora. Further, information was obtained from the Division of Pharmacies and Reimbursement at the Danish Health and Medicines Authority and from the only pharmacy in Denmark producing desiccated thyroid and L-T3 tablets. RESULTS: A total of 384 patients answered the questionnaire, and 293 responders were included. Sixty-nine percent of the responders had six or more symptoms, and 84% reported a treatment effect. Forty-four percent of the responders received their prescriptions from general practitioners; 50% received desiccated thyroid and 28% reported that they adjust their dose themselves. Responders followed by general practitioners more frequently received desiccated thyroid and adjusted their dose themselves. CONCLUSIONS: Increased media focus has changed the prescription pattern of thyroid hormones; European guidelines on T4/T3 combination therapy are not always followed in Denmark and many patients adjust their medication themselves and may therefore be at risk of overtreatment.
Authors: Charlotte Cerqueira; Nils Knudsen; Lars Ovesen; Peter Laurberg; Hans Perrild; Lone Banke Rasmussen; Torben Jørgensen Journal: Eur J Epidemiol Date: 2011-06-10 Impact factor: 8.082
Authors: Peter N Taylor; Ahmed Iqbal; Caroline Minassian; Adrian Sayers; Mohd S Draman; Rosemary Greenwood; William Hamilton; Onyebuchi Okosieme; Vijay Panicker; Sara L Thomas; Colin Dayan Journal: JAMA Intern Med Date: 2014-01 Impact factor: 21.873
Authors: Allan Carlé; Inge Bülow Pedersen; Nils Knudsen; Hans Perrild; Lars Ovesen; Peter Laurberg Journal: Eur J Endocrinol Date: 2014-11 Impact factor: 6.664
Authors: Sarah J Peterson; Anne R Cappola; M Regina Castro; Colin M Dayan; Alan P Farwell; James V Hennessey; Peter A Kopp; Douglas S Ross; Mary H Samuels; Anna M Sawka; Peter N Taylor; Jacqueline Jonklaas; Antonio C Bianco Journal: Thyroid Date: 2018-04-05 Impact factor: 6.568
Authors: Freddy J K Toloza; Nataly R Espinoza Suarez; Omar El Kawkgi; Elizabeth H Golembiewski; Oscar J Ponce; Lixia Yao; Spyridoula Maraka; Naykky M Singh Ospina; Juan P Brito Journal: Medicina (Kaunas) Date: 2020-04-03 Impact factor: 2.430